Kalaris Therapeutics, Inc. (KLRS) › Operating Cash FlowKalaris Therapeutics, Inc. (KLRS) — Operating Cash FlowAnnual figures by period end, from SEC filings.2019-12-31: -$20.16M2020-12-31: -$60.81M2021-12-31: -$106.32M2022-12-31: -$142.05M2023-12-31: -$124.45M2024-12-31: -$20.67M2025-12-31: -$38.37M-$38.37M2019-12-31Operating Cash Flow (USD)2025-12-31Period endedOperating Cash FlowChange YoYSource filing2025-12-31-$38.37M—2026-03-17From 2025-01-012024-12-31-$20.67M—2026-03-17From 2024-01-012023-12-31-$124.45M—2025-03-07From 2023-01-012022-12-31-$142.05M—2024-03-15From 2022-01-012021-12-31-$106.32M—2023-02-15From 2021-01-012020-12-31-$60.81M—2022-02-10From 2020-01-012019-12-31-$20.16M—2021-02-12From 2019-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)